Market Background

There is a surge in interest in AI-based drug discovery and development, leading biopharmaceutical companies to expand their investments in leveraging data science and computing power for novel drug exploration. This trend is largely driven by the expectation that it can reduce costs and time compared to traditional, experiment-centric research. As AI and machine learning technologies expand to the actual candidate substance selection stage, the value of platform companies is increasing.

Strategic Timing

Altares, a private equity firm specializing in the healthcare sector, has undertaken this acquisition to make a full-fledged entry into the AI drug development market. Currently, there is a strong trend among biopharmaceutical companies to utilize external specialized companies rather than build AI solutions in-house, leading Altares to believe that the timing of the acquisition is optimal. This is a strategic move aimed at diversifying the investment portfolio and simultaneously achieving rapid market entry.

Value of Simulations Plus

Simulations Plus provides an in silico modeling platform that predicts the physical and chemical properties of compounds in a computer environment. This technology significantly improves cost-effectiveness by screening candidate substances before direct verification in the laboratory. Furthermore, it continuously updates AI-based prediction algorithms, allowing them to be applied throughout the entire new drug development pipeline.

Future Impact

Altares plans to provide Simulations Plus' technology to existing portfolio companies to accelerate AI-based new drug exploration. This is likely to lead to reduced R&D costs and a shortened timeline for clinical entry for biopharmaceutical companies. At the same time, as competition intensifies in the AI platform market, other investors are also expected to explore similar strategies.